Sensitivity & specificity of 5 trial registers used by the - - PowerPoint PPT Presentation

sensitivity specificity of 5 trial registers
SMART_READER_LITE
LIVE PREVIEW

Sensitivity & specificity of 5 trial registers used by the - - PowerPoint PPT Presentation

12.00-12.15 PM, 31st Oct 2013 Parallel Session 2B - Evidence Sensitivity & specificity of 5 trial registers used by the Cochrane Skin Group Ching-Chi Chi, MD, MMS, DPhil (Oxford) 1-3 and Shu-Hui Wang, MD, MS 4 1 Department of Dermatology &


slide-1
SLIDE 1

Sensitivity & specificity of 5 trial registers used by the Cochrane Skin Group

Ching-Chi Chi, MD, MMS, DPhil (Oxford)1-3 and Shu-Hui Wang, MD, MS4

1Department of Dermatology & Centre for Evidence-Based Medicine, Chang Gung Memorial Hospital,

Chiayi, Taiwan

2Chang Gung University, College of Medicine, Taoyuan, Taiwan 3Cochrane Skin Group, Nottingham, UK 4Department of Dermatology, Far Eastern Memorial Hospital, New Taipei, Taiwan

12.00-12.15 PM, 31st Oct 2013 Parallel Session 2B - Evidence

slide-2
SLIDE 2

Background

  • Cochrane review authors are required to search trials registers

for relevant trials to avoid missing unpublished evidence.

  • The Cochrane Skin Group advises review authors to search:

1. metaRegister of controlled trials (mRCT), 2. ClinicalTrials.gov (CT), 3. World Health Organization International Clinical Trials Registry Platform (ICTRP), 4. Australian New Zealand Clinical Trials Registry (ANZCTR), 5. EU Clinical Trials Register (EUCTR).

  • However, searching multiple trial registers is a tedious task.

31 Oct 2013 ISEHC Dr Ching-Chi Chi, MD, MMS, DPhil (Oxford)

slide-3
SLIDE 3

Objective

  • To compare the sensitivity and specificity of

the five trial registers used by the Cochrane Skin Group in identifying relevant studies.

31 Oct 2013 ISEHC Dr Ching-Chi Chi, MD, MMS, DPhil (Oxford)

slide-4
SLIDE 4

Methods

  • The five registers were searched for relevant studies

for two Cochrane reviews* that the author was involved.

  • The sensitivity of a register was defined as below:

rials relevant t all register a in identified rials relevant t  y Sensitivit register a in identified trials all register a in identified rials relevant t  y Specificit

*The two Cochrane reviews are: #1 Chi CC, Kirtschig G, Baldo M, Brackenbury F, Lewis F, Wojnarowska F. Topical interventions for genital lichen sclerosus. Cochrane Database of Systematic Reviews 2011, Issue 12. Art. No.:

  • CD008240. DOI: 10.1002/14651858.CD008240.pub2.

#2 Lee C, Chi CC, Hsieh SC, Chang CJ, Delamere FM, Peters MC, Kanjirath PP, Anderson PF. Interventions for treatment of herpes simplex labialis (cold sores on the lips). Cochrane Database of Systematic Reviews 2011, Issue 10. Art. No.: CD009375. DOI:10.1002/14651858.CD009375.

31 Oct 2013 ISEHC Dr Ching-Chi Chi, MD, MMS, DPhil (Oxford)

slide-5
SLIDE 5

Results

  • A total of 7 and 48 trials relevant to the first and second

Cochrane review were identified, respectively.

  • For the first Cochrane review, the sensitivity for mRCT, CT,

ICTRP, ANZCTR, and EUCTR was 57%, 57%, 86%, 0%, and 43%,

  • respectively. The specificity was 100%, 80%, 75%, NA, and

75%, respectively. A completed and published trial was mislabelled as ‘recruiting’ or ‘unknown’ in the mRCT, CT, and ICTRP.

  • For the second Cochrane review, the sensitivity for mRCT,

ClinicalTrials.gov, ICTRP, and ANZCTR was 40%, 56%, 81%, 2%, and 25%, respectively. The respective specificity was 76%, 79%, 100%, 3%, and 100%. A completed trial was mislabelled as ‘active, not recruiting’ in the mRCT.

31 Oct 2013 ISEHC Dr Ching-Chi Chi, MD, MMS, DPhil (Oxford)

slide-6
SLIDE 6

Sensitivity in review #1 Sensitivity in review #2 Specificity in review #1 Specificity in review #2 Study status correctly labeled in review #1 Study status correctly labeled in review #2

mRCT

4/7 (57%) 19/48 (40%) 4/4 (100%) 19/25 (76%) 3/4 (75%) 18/19 (95%)

CT

4/7 (57%) 27/48 (56%) 4/5 (80%) 27/34 (79%) 3/4 (75%) 27/27 (100%)

ICTRP 6/7 (86%) 39/48 (81%) 6/8 (75%) 39/39 (100%) 5/6 (83%) 5/5 (100%) ANZCTR 0/7 (0%) 1/48 (2%) 0/0 (NA) 1/34 (3%) NA 1/1 (100%) EUCTR

3/7 (43%) 12/48 (25%) 3/4 (75%) 12/12 (100%) 3/3 (100%) 12/12 (100%)

  • Overall, the ICTRP was the best, while the ANZCTR was the

worst.

  • Apparently, no single trial register encompasses all relevant

trials and provide correct information about study status.

31 Oct 2013 ISEHC Dr Ching-Chi Chi, MD, MMS, DPhil (Oxford)

slide-7
SLIDE 7

Portal

  • Only simple search: mRCT
  • Advanced search provided by CT, ICTRP, ANZCTR, and EUCTR
  • Lacking search history, not as powerful as bibliographic databases

31 Oct 2013 ISEHC Dr Ching-Chi Chi, MD, MMS, DPhil (Oxford)

slide-8
SLIDE 8

Search results

  • Various formats.
  • None could be exported to

references manager softwares, such as EndNote.

31 Oct 2013 ISEHC Dr Ching-Chi Chi, MD, MMS, DPhil (Oxford)

slide-9
SLIDE 9

Study status

  • No trial registers provided

complete correct information about the study status.

  • A trial already published in

June 2011 was still labelled as ‘recruiting’ in mRCT and CT.

31 Oct 2013 ISEHC Dr Ching-Chi Chi, MD, MMS, DPhil (Oxford)

slide-10
SLIDE 10

Limits

  • The limitation of this result was based on the

searching exercise for two Cochrane reviews that the authors were involved.

31 Oct 2013 ISEHC Dr Ching-Chi Chi, MD, MMS, DPhil (Oxford)

slide-11
SLIDE 11

Bottom line

  • Authors should keep current strategy of

searching all trial registers, and recheck the status information provided by trial registers.

  • There is room for improvement of the

sensitivity and the accuracy of trial status information by frequent updating and collaboration between registers.

31 Oct 2013 ISEHC Dr Ching-Chi Chi, MD, MMS, DPhil (Oxford)

slide-12
SLIDE 12

Abstract submission from 15 Feb, 2014 Very early registration by 31 March, 2014 early registration by 30 June, 2014